Safety and efficacy of PEG-rhG-CSF as primary prophylaxis for neutropenia in gastrointestinal cancer patients receiving combination chemotherapy including oral agents: a prospective, exploratory, non-randomized controlled study
Authors:
Open Access
- 14 April 2026
- journal article
- clinical trial-article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1764358
Abstract
Purpose: The safety and efficacy of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) for prevention of chemotherapy-induced neutropenia (CIN) in patients undergoing oral chemotherapy remain unclear. This study aimed to investigate the safety and efficacy of PEG-rhG-CSF as primary prophylaxis for CIN in gastrointestinal (GI) cancer patients receiving combination chemotherapy regimens that include oral chemotherapy agents. Methods: This is a prospective, single-center, open-label, exploratory, non-randomized controlled study. GI cancer patients was treated with intravenous oxaliplatin (130mg/m 2 on day 1) combined with either oral capecitabine (1000mg/m 2 ) or S−1 (an oral fluoropyrimidine combination of tegafur, gimeracil, and oteracil potassium; 40–60 mg) administered twice daily on days 1–14 of a 3−week cycle. The treatment group received subcutaneous injection of PEG-rhG-CSF (6mg) 24 hours after oxaliplatin, while the control group received no primary prophylaxis. The primary endpoint was safety, and secondary endpoints included the incidence of CIN. Results: Between March 2022 and January 2023, 49 patients were screened, and 43 patients who completed at least two treatment cycles were included in the final analysis (26 in treatment group and 17 in control group). The overall adverse events (AEs) did not differ statistically (93.8% vs 100.0%, p = 0.542). For grade ≥ 3 AEs, the incidence of neutropenia was significantly lower in the treatment group compared to the control group (3.1% vs 35.3%, p = 0.005). No significant differences were observed in the rates of grade ≥ 3 thrombocytopenia (6.3% vs 17.6%, p = 0.326) and leukopenia (3.1% vs 0.0%, p = 1.000). Grade≥2 CIN was significantly lower in the treatment group (25.0% vs. 76.5%, p < 0.001). Conclusion: In GI cancer patients on oral agents, primary PEG-rhG-CSF prophylaxis was well-tolerated and reduced grade ≥2 CIN, though randomized studies are needed. Clinical Trial Registration: https://www.chictr.org.cn , identifier ChiCTR2100054854.Keywords
This publication has 27 references indexed in Scilit:
- Localised rectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2025
- The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of colorectal cancer, 2024 updateCancer Communications, 2024
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancerESMO Open, 2024
- The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023Cancer Communications, 2023
- Clinical use of lenvatinib in patients with previous renal and/or hepatic impairment and radioiodine‐refractory differentiated thyroid cancerCancer Medicine, 2022
- Effect of concomitant use of G-CSF and myelosuppressive chemotherapy on bone marrow and peripheral granulocytes in a mouse modelMedical Oncology, 2022
- The efficacy and safety of neoadjuvant chemotherapy on patients with advanced gastric cancer: A multicenter randomized clinical trialCancer Medicine, 2020
- Treatment-Related Complications of Systemic Therapy and RadiotherapyJAMA Oncology, 2019
- Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: An overview about well-established and recently emerging clinical dataCritical Reviews in Oncology/Hematology, 2017
- Risk of mortality in patients with cancer who experience febrile neutropeniaCancer, 2010